Jupizomib 2 Injection contains Bortezomib 2 mg, a potent proteasome inhibitor indicated for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib exerts its antineoplastic effects by reversibly inhibiting the 26S proteasome, disrupting the regulated degradation of ubiquitinated proteins, thereby inducing apoptosis in malignant cells. Jupizomib 2 Injection is administered via intravenous or subcutaneous routes, with dosing schedules tailored to individual patient response and tolerability. Clinical trials have demonstrated its efficacy in both newly diagnosed and relapsed/refractory multiple myeloma, often in combination with other chemotherapeutic agents or corticosteroids. Common adverse reactions include peripheral neuropathy, thrombocytopenia, neutropenia, gastrointestinal disturbances, and fatigue. Due to its immunosuppressive effects, patients should be monitored for infections and appropriate prophylactic measures considered. Caution is advised in patients with hepatic impairment, and dose adjustments may be necessary. Jupizomib 2 Injection is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. Regular hematologic and neurologic assessments are recommended during therapy to detect and manage potential toxicities promptly. This medication should be administered under the supervision of a healthcare professional experienced in oncology therapeutics.